Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
— — — — — 0.00 — —
P/S ratio
— — — — — 3,065.12 — —
Altman Z″-Score (non-manufacturers)
— — — — — 3.50 — —
P/FCF ratio
— — — — — 0.00 — —
P/Operating CF
— — — — — (25.14) — —
P/B ratio
— — — — — 0.00 — —
EV/Sales
— — — — — 1,313.57 — —
EV/EBITDA
— — — — — 0.00 — —
EV/FCF
— — — — — (2.25) — —
Current Ratio
39.53 15.76 15.22 8.22 11.22 18.53 6.54 —
Net Debt/EBITDA
(0.11) 0.44 0.46 0.92 2.97 7.24 1.35 —
Debt/Equity
0.74 0.50 0.36 0.20 0.00 0.00 0.00 —
ROE
(50.39%) (37.51%) (52.96%) (48.58%) (60.82%) 162.35% 28.06% —
ROA
(30.56%) (25.16%) (38.65%) (40.87%) (33.76%) (22.98%) (137.65%) —
ROIC
(40.13%) (33.19%) (64.02%) (80.86%) (96.17%) 0.00% 0.00% —
Return on Tangible Assets
(38.23%) (30.14%) (54.03%) (51.49%) (28.79%) (13.09%) (80.96%) —
Average Days of Receivables
— — — — — 0.00 — —
Earnings Yield
— — — — — (8.92%) — —
Free Cash Flow Yield
— — — — — (19.02%) — —
Free Cash Flow per Share
(5.49) (8.56) (15.79) (40.88) (33.96) (100.55) (9.29) —
Book value per Share
17.08 26.03 34.72 56.15 104.76 (49.50) (11.63) —
Free Cash Flow
(36.62) (55.70) (102.69) (264.75) (179.97) (80.43) (5.50) —
EV/EBIT
— — — — — 0.00 — —
Other line items

Show all line items

Columns are period end dates